We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tools Designed to Study Genomic Instability

By LabMedica International staff writers
Posted on 01 Jul 2010
A new second-generation poly-adenylyltransferase [ADP]-ribose polymerase (PARP) in vivo pharmacodynamic assay that accurately measures net poly(ADP-ribose) (PAR) levels in cellular extracts, is being used to document differences in PAR levels in human tumor lysates from a variety of tissues, organs, and xenografts.

PARP is a protein involved in a number of cellular processes including catalyzing the nicotinamide adenine dinucleotide (NAD)-dependent addition of PAR onto itself and other adjacent nuclear proteins. PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia, and neurodegeneration. More recently, the discovery that breast cancers deficient in homologous recombination are sensitive to nontoxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.

Amsbio's (Abingdon, UK) PARP in vivo pharmacodynamic assay uses a validated sample processing regime and a chemiluminescent, sandwich enzyme-linked immunosorbent assay (ELISA) format, with precoated 96-stripwell plates. The assay reports PAR level with high signal to noise ratio; sensitivity of 2 pg/mL and a linear dynamic range to 1,000 pg/mL. Consequently, the PARP in vivo pharmacodynamic assay offers an exciting new application that provides evidence of drug action on molecular targets and generates baseline values that may be used to stratify patient response to therapy.

AMS Biotechnology (Amsbio) is an international provider of products and services for life sciences research. The Amsbio range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.

Related Links:
Amsbio



Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays
New
Human Immunodeficiency Virus Assay
RealLine HIV Quantitative Kit

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries